Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

Código QR

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

Werner Poewe1, Angelo Antonini2, Jan CM Zijlmans3, Pierre R Burkhard4, François Vingerhoets51Department of Neurology, Medical University of Innsbruck, Austria; 2Parkinson Department, IRCCS San Camillo, Venice, and University of Padua, Italy; 3Department of Neurology, Amphia Hospital, Bred...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Werner Poewe, Angelo Antonini, Jan CM Zijlmans, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	levodopa motor fluctuations dyskinesia Parkinson's disease Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/e01cf434dee341bbbcb3f66eb12a8f0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel AB, et al.
Publicado: (2018)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: José-Francisco Rocha, et al.
Publicado: (2021)

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
por: Daniel D Truong
Publicado: (2009)

Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006)

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
por: A Ahmadi Ahangar, et al.
Publicado: (2002)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu N, et al.
Publicado: (2018)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser RA, et al.
Publicado: (2018)

Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
por: Cao,Xuebing, et al.
Publicado: (2016)

Comparación farmacocinética de Sinemetây Grifoparkinâ (levodopa/carbidopa 250/25 mg) en pacientes con enfermedad de Parkinson avanzada: un estudio con dosis única
por: Chaná C,Pedro, et al.
Publicado: (2003)

Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment
por: Kasemsap N, et al.
Publicado: (2016)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman DY, et al.
Publicado: (2018)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
por: Szász JA, et al.
Publicado: (2019)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Yi Wu, et al.
Publicado: (2021)

Síndrome neuroléptico maligno-like como complicación en enfermedad de Parkinson: Desenlace fatal. Reporte de un caso y revisión de la literatura
por: Salinas S,Carlos, et al.
Publicado: (2014)

Consideraciones sobre las complicaciones motoras y neurotoxicidad de la levodopa en la enfermedad de Parkinson
por: Venegas F.,Pablo
Publicado: (2005)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
por: Modugno N, et al.
Publicado: (2020)

Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease
por: Hirofumi Matsuyama, et al.
Publicado: (2021)

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
por: Szász JA, et al.
Publicado: (2019)

Relationships between Freezing of Gait Severity and Cognitive Deficits in Parkinson’s Disease
por: Jamie L. Scholl, et al.
Publicado: (2021)

DEVELOPMENT OF A MODIFIED CARBON ELECTRODE WITH IONIC LIQUID AND ITS APPLICATION FOR ELECTROCATALYTIC OXIDATION AND VOLTAMMETRIC DETERMINATION OF LEVODOPA
por: MONCADA,V, et al.
Publicado: (2014)

ДИФФЕРЕНЦИРОВАННОЕ КОМПЛЕКСНОЕ ЛЕЧЕНИЕ ПАЦИЕНТОВ, СТРАДАЮЩИХ БОЛЕЗНЬЮ ПАРКИНСОНА, С УЧЁТОМ СТЕПЕНИ АТРОФИЧЕСКИХ ИЗМЕНЕНИЙ ВЕЩЕСТВА ГОЛОВНОГО МОЗГА
por: V. A. Chipizubov, et al.
Publicado: (2017)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin VA, et al.
Publicado: (2020)

Bilateral Globus Pallidus Interna Combined With Subthalamic Nucleus Variable Frequency Deep Brain Stimulation in the Treatment of Young-Onset Parkinson's Disease With Refractory Dyskinesia: A Case Report
por: Bowen Chang, et al.
Publicado: (2021)

Depression and Related Factors in Patients with Parkinson’s Disease at High Altitude
por: Cao Y, et al.
Publicado: (2021)

Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson’s Disease
por: Ezgi Saylam, et al.
Publicado: (2021)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Retraction]
por: Hinz M, et al.
Publicado: (2021)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

Electrocatalytic determination of levodopa in presence of cabergoline using carbon paste electrode modified with graphene quantum dots/2-chlorobenzoyl ferrocene/ionic liquid
por: Peyman Mohammadzadeh Jahani
Publicado: (2021)

Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson’s disease
por: Berardelli I, et al.
Publicado: (2018)

Long-term changes in short-interval intracortical facilitation modulate motor cortex plasticity and L-dopa-induced dyskinesia in Parkinson's disease
por: Andrea Guerra, et al.
Publicado: (2022)

Mette Kunøe - Still going strong
por: Kirsten Gomard
Publicado: (2007)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012)

Atypical parkinsonism and self‐mutilation: A new lens on the old concept
por: Mehri Salari, et al.
Publicado: (2021)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Tian-Sin Fan, et al.
Publicado: (2021)

Parkinson's disease

Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
por: Murakami H, et al.
Publicado: (2017)

NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and ß-arrestin-1 expression in parkinsonian rats
por: Wu N, et al.
Publicado: (2013)

Parkinson’s Disease-Associated Melanin Steal [Retraction]
por: Hinz M, et al.
Publicado: (2021)

Nervonic acid amends motor disorder in a mouse model of Parkinson’s disease
por: Hu Dandong, et al.
Publicado: (2021)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas P, et al.
Publicado: (2013)